Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 23

Results For "PIP"

890 News Found

Freenome strikes SPAC deal to go public in 2026
Biotech | December 08, 2025

Freenome strikes SPAC deal to go public in 2026

Freenome expects the combined company to receive approximately $330 million in proceeds at closing


B Braun unveils ready-to-use antibiotic system
R&D | December 08, 2025

B Braun unveils ready-to-use antibiotic system

DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation


Bayer advances fight against rare kidney disease with new experimental drug
R&D | December 07, 2025

Bayer advances fight against rare kidney disease with new experimental drug

Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes


Excelsior Sciences raises $95 million for drug discovery with AI-ready chemistry
Startup | December 05, 2025

Excelsior Sciences raises $95 million for drug discovery with AI-ready chemistry

Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions


Philips unveils helium-free 3.0T MRI innovation at RSNA 2025
News | December 04, 2025

Philips unveils helium-free 3.0T MRI innovation at RSNA 2025

The BlueSeal Horizon 3.0T platform incorporates advanced magnet technology


ZIM Laboratories receives CDSCO approval for Naproxen + Esomeprazole capsules
Drug Approval | December 04, 2025

ZIM Laboratories receives CDSCO approval for Naproxen + Esomeprazole capsules

Grant of Permission to manufacture and market FDC of Naproxen Delayed Release and Esomeprazole capsule (375mg/500mg + 20mg/20mg)


Merck unveils first human data for Alzheimer’s candidates
Clinical Trials | December 03, 2025

Merck unveils first human data for Alzheimer’s candidates

The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration


Data deluge at ASH: Bristol Myers Squibb showcases breakthroughs across blood cancers
Clinical Trials | December 02, 2025

Data deluge at ASH: Bristol Myers Squibb showcases breakthroughs across blood cancers

Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM